Abiopharma

USBC, INC. (USBC) Announces Regulatory Update USBC, INC. (USBC) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: • Applications: NDA (New Drug Application) • Regulatory Agencies: EMA (European Medicines Agency) • Status: Rejected, Delayed Clinical Development: Management Commentary: '"Regaining full NYSE compliance reflects USBC’s commitment to financial discipline as we move toward the future launch of the tokenized deposit offering," said Greg Kidd'